Literature DB >> 33168605

Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia.

Ana Motos1,2,3,4, Gianluigi Li Bassi1,2,3,5, Francesco Pagliara1,6,7, Laia Fernandez-Barat1,2,3,4, Hua Yang1, Eli Aguilera Xiol1,2,3, Tarek Senussi1,6,7, Francesco A Idone1,8,9, Chiara Travierso1,10,11,12, Chiara Chiurazzi1,13, Rosanel Amaro1,2,3,4, Minlan Yang1,4, Joaquim Bobi1,2, Montserrat Rigol1,2, David P Nicolau14, Gerard Frigola15, Roberto Cabrera1,2,3, Jose Ramirez15, Paolo Pelosi6,7, Francesco Blasi11,12, Massimo Antonelli8,9, Antonio Artigas16, Jordi Vila17, Marin Kollef18, Antoni Torres19,2,3,4.   

Abstract

The rising frequency of multidrug-resistant and extensively drug-resistant (MDR/XDR) pathogens is making more frequent the inappropriate empirical antimicrobial therapy (IEAT) in nosocomial pneumonia, which is associated with increased mortality. We aim to determine the short-term benefits of appropriate empirical antimicrobial treatment (AEAT) with ceftolozane/tazobactam (C/T) compared with IEAT with piperacillin/tazobactam (TZP) in MDR Pseudomonas aeruginosa pneumonia. Twenty-one pigs with pneumonia caused by an XDR P. aeruginosa strain (susceptible to C/T but resistant to TZP) were ventilated for up to 72 h. Twenty-four hours after bacterial challenge, animals were randomized to receive 2-day treatment with either intravenous saline (untreated) or 25 to 50 mg of C/T per kg body weight (AEAT) or 200 to 225 mg of TZP per kg (IEAT) every 8 h. The primary outcome was the P. aeruginosa burden in lung tissue and the histopathology injury. P. aeruginosa burden in tracheal secretions and bronchoalveolar lavage (BAL) fluid, the development of antibiotic resistance, and inflammatory markers were secondary outcomes. Overall, P. aeruginosa lung burden was 5.30 (range, 4.00 to 6.30), 4.04 (3.64 to 4.51), and 4.04 (3.05 to 4.88) log10CFU/g in the untreated, AEAT, and IEAT groups, respectively (P = 0.299), without histopathological differences (P = 0.556). In contrast, in tracheal secretions (P < 0.001) and BAL fluid (P = 0.002), bactericidal efficacy was higher in the AEAT group. An increased MIC to TZP was found in 3 animals, while resistance to C/T did not develop. Interleukin-1β (IL-1β) was significantly downregulated by AEAT in comparison to other groups (P = 0.031). In a mechanically ventilated swine model of XDR P. aeruginosa pneumonia, appropriate initial treatment with C/T decreased respiratory secretions' bacterial burden, prevented development of resistance, achieved the pharmacodynamic target, and may have reduced systemic inflammation. However, after only 2 days of treatment, P. aeruginosa tissue concentrations were moderately affected.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  Pseudomonas aeruginosazzm321990; animal models; appropriate empirical antimicrobial treatment; mechanical ventilation; pneumonia

Mesh:

Substances:

Year:  2021        PMID: 33168605      PMCID: PMC7848990          DOI: 10.1128/AAC.01899-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

1.  Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.

Authors:  Gurudatt Chandorkar; Jennifer A Huntington; Mark H Gotfried; Keith A Rodvold; Obiamiwe Umeh
Journal:  J Antimicrob Chemother       Date:  2012-07-06       Impact factor: 5.790

2.  A novel porcine model of ventilator-associated pneumonia caused by oropharyngeal challenge with Pseudomonas aeruginosa.

Authors:  Gianluigi Li Bassi; Montserrat Rigol; Joan-Daniel Marti; Lina Saucedo; Otavio T Ranzani; Ignasi Roca; Maria Cabanas; Laura Muñoz; Valeria Giunta; Nestor Luque; Mariano Rinaudo; Mariano Esperatti; Laia Fernandez-Barat; Miquel Ferrer; Jordi Vila; Jose Ramirez; Antoni Torres
Journal:  Anesthesiology       Date:  2014-05       Impact factor: 7.892

3.  In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.

Authors:  Shinobu Takeda; Toru Nakai; Yoshimi Wakai; Fumiaki Ikeda; Kazuo Hatano
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

Review 4.  Ceftolozane/tazobactam: place in therapy.

Authors:  Daniele Roberto Giacobbe; Matteo Bassetti; Francesco Giuseppe De Rosa; Valerio Del Bono; Paolo Antonio Grossi; Francesco Menichetti; Federico Pea; Gian Maria Rossolini; Mario Tumbarello; Pierluigi Viale; Claudio Viscoli
Journal:  Expert Rev Anti Infect Ther       Date:  2018-03-09       Impact factor: 5.091

5.  Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.

Authors:  Benjamin Miller; Ellie Hershberger; David Benziger; Mymy Trinh; Ian Friedland
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

6.  Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia.

Authors:  C M Luna; P Vujacich; M S Niederman; C Vay; C Gherardi; J Matera; E C Jolly
Journal:  Chest       Date:  1997-03       Impact factor: 9.410

7.  Experimental severe Pseudomonas aeruginosa pneumonia and antibiotic therapy in piglets receiving mechanical ventilation.

Authors:  Carlos M Luna; Sebastián Baquero; Sebastián Gando; Juan Risso Patrón; Joaquín García Morato; Oriol Sibila; Rubén Absi; Angela Famiglietti; Carlos A Vay; Florencia Von Stecher; Carlos Agustí; Antoni Torres
Journal:  Chest       Date:  2007-08       Impact factor: 9.410

8.  Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.

Authors:  Alan J Xiao; Benjamin W Miller; Jennifer A Huntington; David P Nicolau
Journal:  J Clin Pharmacol       Date:  2015-08-25       Impact factor: 3.126

9.  Antimicrobial Stewardship Opportunities in Critically Ill Patients with Gram-Negative Lower Respiratory Tract Infections: A Multicenter Cross-Sectional Analysis.

Authors:  Kimberly C Claeys; Evan J Zasowski; Trang D Trinh; Abdalhamid M Lagnf; Susan L Davis; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2017-11-21

10.  Development of an HPLC-MS/MS method for the determination of ceftolozane/tazobactam in bronchoalveolar lavage fluid.

Authors:  Christina A Sutherland; Can Ozbal; David P Nicolau
Journal:  Future Sci OA       Date:  2018-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.